— Van Karlyle Morris, MD, goes over the success of checkpoint blockade in this population
by Greg Laub, Director, Video, MedPage Today
June 30, 2023
In this special MedPage Today video, Van Karlyle Morris, MD, of the University of Texas MD Anderson Cancer Center in Houston, goes over the adoption of immunotherapy for clients with microsatellite instability [MSI]-high or lacking inequality repair work (dMMR) colorectal cancers.
Following is a records of his remarks:
Among the actually interesting advances recently has actually been the adoption of immunotherapy in clients with MSI-high or lacking inequality repair work colorectal cancers. And while the preliminary information came out years earlier now in clients with metastatic illness, what we’ve seen in the in 2015 with information from dostarlimab [Jemperli] in clients with rectal cancer and with the specific niche information in clients with localized colon cancer, is that the advantage of immune checkpoint blockade treatment can definitely be extended, most likely throughout all phases of clients with MSI-high colorectal cancer.
When I consider ASCO in 2015, we saw in a little associate of clients from Memorial Sloan Kettering– Dr. [Andrea] Cercek provided information for clients with localized rectal cancer– a total scientific action rate of 100% in their preliminary mate of clients they took a look at. And obviously, this is extremely, really amazing since that provided clients a chance for a most likely alleviative result without ever needing to get, possibly, chemotherapy, radiotherapy, or surgical treatment.
I believe among the important things in real-world experience and among the important things that we’ve seen in more research studies at our organization, at MD Anderson, Dr. Kaysia Ludford led a research study released in the Journal of Clinical Oncology this year in clients with localized MSI-high/deficient mismatched repair work intestinal cancers. In